Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer

Human Pathology

Volumn 38, Issue 11, 2007, Pages 1603-1610

  Cho, Yong Beom ^a   Lee, Woo Yong ^a   Song, Sang Yong ^a   Shin, Hee Jung ^a   Yun, Seong Hyeon ^a   Chun, Ho Kyung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Colorectal cancer; MMP 2; MMP 9; Node negative; Prognosis; RECK

Indexed keywords

FLUOROURACIL; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN RECK; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROGNOSIS;

EID: 35348901941     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.03.018     Document Type: Article

References (33)

1. Macdonald J.S. Adjuvant therapy of colon cancer. CA Cancer J Clin 49 (1999) 202-219
2. Fielding L.P., Phillips R.K., Fry J.S., and Hittinger R. Prediction of outcome after curative resection for large bowel cancer. Lancet 2 (1986) 904-907
3. O'Connell M.J., Schaid D.J., Ganju V., Cunningham J., Kovach J.S., and Thibodeau S.N. Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis?. Cancer 70 (1992) 1732-1739
4. Wagenaar-Miller R.A., Gorden L., and Matrisian L.M. Matrix metalloproteinases in colorectal cancer: is it worth talking about?. Cancer Metastasis Rev 23 (2004) 119-135
5. Mook O.R., Frederiks W.M., Van C., and Noorden J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705 (2004) 69-89
6. Kitayama H., Sugimoto Y., Matsuzaki T., Ikawa Y., and Noda M. A ras-related gene with transformation suppressor activity. Cell 56 (1989) 77-84
7. Noda M., Kitayama H., Matsuzakie T., et al. Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes. Proc Natl Acad Sci U S A 86 (1989) 162-166
8. Takahashi C., Akiyama N., Matsuzaki T., Takai S., Kitayama H., and Noda M. Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene. Oncogene 12 (1996) 2137-2146
9. Takahashi C., Sheng Z., Horan T.P., et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A 95 (1998) 13221-13226
10. Sasahara R.M., Takahashi C., and Noda M. Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem Biophys Res Commun 264 (1999) 668-675
11. Oh J., Takahashi R., Kondo S., et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107 (2001) 789-800
12. Weaver V.M. Membrane-associated MMP regulators: novel cell adhesion tumor suppressor proteins?. Dev Cell 2 (2002) 6-7
13. Jass J.R., and Sobin L.H. Histological typing of intestinal tumors. In: Cho Y.B. (Ed). International histological classifications of tumors. 2nd ed. (1989), Springer-Verlag, Berlin
14. Takenaka K., Ishikawa S., Yanagihara K., et al. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer. Ann Surg Oncol 12 (2005) 817-824
15. Kikuchi R., Noguchi T., Takeno S., Kubo N., and Uchida Y. Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br J Cancer 83 (2000) 215-218
16. van derJagt M.F., Sweep F.C., Waas E.T., et al. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 237 (2006) 289-297
17. Masui T., Doi R., Koshiba T., et al. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res 9 (2003) 1779-1784
18. Takenaka K., Ishikawa S., Kawano Y., et al. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer 40 (2004) 1617-1623
19. Stetler-Stevenson W.G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9 (1990) 289-303
20. Liotta L.A., and Stetler-Stevenson W.G. Metalloproteinases and cancer invasion. Semin Cancer Biol 1 (1990) 99-106
21. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89 (1997) 1260-1270
22. Jadhav U., Chigurupati S., Lakka S.S., and Mohanam S. Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol 25 (2004) 1407-1414
23. Folgueras A.R., Pendas A.M., Sanchez L.M., and Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48 (2004) 411-424
24. Levy A.T., Cioce V., Sobel M.E., et al. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51 (1991) 439-444
25. Ring P., Johansson K., Hoyhtya M., Rubin K., and Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage. Br J Cancer 76 (1997) 805-811
26. Zeng Z.S., Huang Y., Cohen A.M., and Guillem J.G. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14 (1996) 3133-3140
27. Ogata Y., Matono K., Sasatomi T., et al. The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol 57 (2006) 577-583
28. Burdy G., Panis Y., Alves A., Nemeth J., Lavergne-Slove A., and Valleur P. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 44 (2001) 1682-1688
29. Swanson R.S., Compton C.C., Stewart A.K., and Bland K.I. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10 (2003) 65-71
30. Benson III A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004) 3408-3419
31. Tepper J.E., O'Connell M.J., Niedzwiecki D., et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19 (2001) 157-163
32. Wong J.H., Severino R., Honnebier M.B., Tom P., and Namiki T.S. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 17 (1999) 2896-2900
33. Goldstein N.S., Sanford W., Coffey M., and Layfield L.J. Lymph node recovery from colorectal resection specimens removed for adenocarcinoma. Trends over time and a recommendation for a minimum number of lymph nodes to be recovered. Am J Clin Pathol 106 (1996) 209-216